Ethinyl estradiol sulfonate

Ethinyl estradiol sulfonate
Clinical data
Trade names Turisteron
Routes of
Oral, intramuscular injection
CAS Number 28913-23-7
PubChem (CID) 68582
ChemSpider 61851
KEGG D07928
Chemical and physical data
Formula C23H30O4S
Molar mass 402.5469 g/mol
3D model (Jmol) Interactive image

Ethinyl estradiol sulfonate (EES) (brand name Turisteron), also known as ethinyl estradiol isopropylsulfonate or ethinyl estradiol propanesulfate, as well as 17α-ethinyl-3-isopropylsulfonyloxyestradiol, is a synthetic, steroidal estrogen that is marketed in Germany.[1][2] It is an ester of ethinyl estradiol, and acts as a long-acting (half-life of six days),[3] orally active depot form of the drug.[2] EES is used in the treatment of advanced breast and prostate cancers.[2][3][4][5] The drug is very potent (used clinically at a dosage of 1–2 mg weekly via intramuscular injection) and a powerful antigonadotropin, capable of suppressing circulating testosterone concentrations to levels comparable to those seen with castration (less than 1–3% of initial values).[5][6] As such, EES is a strong functional antiandrogen.[7]

See also


  1. Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 412–. ISBN 978-3-88763-075-1.
  2. 1 2 3 Michael Oettel; Ekkehard Schillinger (6 December 2012). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Springer Science & Business Media. pp. 540–542. doi:10.1007/978-3-642-60107-1. ISBN 978-3-642-60107-1.
  3. 1 2 Gürtler R, Tanneberger S, Bodek B, Morack G (1982). "[Clinical experience with the depot estrogen Turisteron in the treatment of metastatic breast cancer (author's transl)]". Arch. Geschwulstforsch. (in German). 52 (2): 129–39. PMID 7103689.
  4. S. Monfardini; K. Brunner; D. Crowther; S. Eckhardt; D. Olive; S. Tanneberger; A. Veronesi; J.M.A. Whitehouse; R. Wittes (1987). Manual of Adult and Paediatric Medical Oncology. Springer Science & Business Media. pp. 196–. doi:10.1007/978-3-642-82489-0. ISBN 978-3-642-82489-0.
  5. 1 2 Dörner G, Schnorr D, Stahl F, Rohde W (1985). "Successful treatment of prostatic cancer with the orally active depot estrogen ethinylestradiol sulfonate (Turisteron)". Exp. Clin. Endocrinol. 86 (2): 190–6. doi:10.1055/s-0029-1210486. PMID 3912197.
  6. Stahl F, Schnorr D, Bär CM, Fröhlich G, Dörner G (1989). "Suppression of plasma androgen levels with a combination therapy of depot-estrogen (Turisteron) and Dexamethasone in patients with prostatic cancer". Exp. Clin. Endocrinol. 94 (3): 239–43. doi:10.1055/s-0029-1210905. PMID 2630306.
  7. Schnorr D, Dörner G, Stahl F, Rohde W, Guddat HM (1987). "[Conservative therapy of prostate cancer using Turisteron]". Z Urol Nephrol (in German). 80 (3): 149–57. PMID 3111122.

This article is issued from Wikipedia - version of the 11/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.